NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that the American Journal of Perinatology has published the results of a blinded, retrospective study of 48 asymptomatic, healthy pregnant women that demonstrates the feasibility of assessing biomarkers associated with blood based microvesicles/exosomes for spontaneous preterm birth (SPTB) risk.
Advertisements